• Healthcare
  • HealthTech

Ōura Partners with Stelo to Launch AI-Powered Meal and Glucose Tracking

3 minute read

By Tech Icons
10:58 am
Save

Smart Ring Maker Expands Health Tracking with AI-Powered Food Recognition and 15-Minute Glucose Readings

Three Key Facts

  • Ōura integrates with Stelo by Dexcom to provide AI-driven meal and glucose tracking through its smart ring and app ecosystem
  • New features include AI-powered meal photo recognition and continuous glucose monitoring with readings every 15 minutes
  • Stelo glucose biosensor is available for $99, requiring no prescription and lasting 15 days per sensor

Introduction

A breakthrough in personal health monitoring emerges as Ōura partners with Stelo by Dexcom to transform how users track their metabolic health. The collaboration, detailed in VentureBeat, introduces AI-powered meal tracking and glucose monitoring features that integrate seamlessly with Ōura’s existing health metrics.

Key Developments

The partnership introduces two groundbreaking features: AI-powered meal tracking through photo recognition and continuous glucose monitoring via Dexcom’s biosensor technology. Users can now photograph their meals for instant nutritional analysis, while the Stelo sensor provides glucose readings every 15 minutes directly to the Ōura app.

Holly Shelton, Ōura’s Chief Product Officer, emphasizes the company’s commitment to AI integration: “Our product roadmap for this year is built on a robust investment in AI-forward offerings.” This approach aims to provide users with deeper insights into their nutritional choices and metabolic responses.

Market Impact

With over 800 million people globally facing obesity-related challenges, this integration addresses critical health monitoring needs. The Stelo biosensor, priced at $99 and available without prescription, makes professional-grade glucose monitoring accessible to a broader consumer base.

Jake Leach from Dexcom notes that the integration creates “a personalized metabolic health experience,” combining lifestyle data with precise glucose monitoring in ways previously unavailable to consumers.

Strategic Insights

Ōura’s approach focuses on pattern recognition rather than individual measurements. Shyamal Patel, Ōura’s Senior VP of Science, stresses the importance of understanding long-term trends over isolated readings, promoting a balanced approach to dietary choices.

The integration leverages AI through Ōura Advisor to provide personalized insights, helping users understand how their lifestyle choices affect their metabolic health without prescriptive judgment.

Expert Opinions and Data

Healthcare professionals praise the system’s comprehensive approach to metabolic health monitoring. The technology combines Dexcom’s established glucose monitoring expertise with Ōura’s sophisticated activity and sleep tracking capabilities.

Initial data suggests that users benefit from seeing the direct relationship between their dietary choices and glucose responses. The system’s ability to provide immediate feedback through AI-driven analysis helps users make more informed decisions about their health.

Moving Forward

The Meals and Glucose features are now available on iOS and Android devices in the U.S., with international expansion planned. This integration represents a significant step in making professional-grade health monitoring accessible to consumers, strengthening Ōura’s position in the digital health market.

Related News

Tencent Music Shares Hit Record High After Strong Q2 Earnings

Read more

Disney Posts Mixed Q1 as Parks Surge Offsets Streaming Strain

Read more

Digital Wellness Study: Face-Down Phones Boost Battery Life

Read more

Amazon Launches 27 Kuiper Satellites, Doubles Orbital Internet Fleet

Read more

Zuckerberg Offers $100+ Salaries to Build Meta's Superintelligence Team

Read more

States of Power: Sovereign Capital and the New Technological Order

Read more

HealthTech News

View All
Hims & Hers Health Q2 2026 earnings and financial results, showing the company amid record revenue growth, international expansion following the Eucalyptus acquisition, weight loss and GLP-1 business changes, and mounting legal and regulatory risk from the FTC privacy lawsuit.

Hims & Hers Posts Record Revenue Amid Mounting Legal Risk

Read more
Scientist holding a laboratory test tube during pharmaceutical research at Novo Nordisk, illustrating Ziltivekimab, ZEUS trial, IL-6 inhibitor research, cardiovascular inflammation therapy, heart disease treatment and clinical drug development.

Novo Nordisk's Ziltivekimab Fails Pivotal Heart Trial

Read more
Eli Lilly Q1 2026 results reflecting tirzepatide sales surge, Mounjaro and Zepbound growth, and expanding GLP-1 drug market demand

Eli Lilly Posts 56% Revenue Surge as Incretin Empire Expands

Read more